Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 03, 2022 07:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Reports First Quarter 2022 Financial Results and Business Update

-- Patient identification and physician engagement ongoing in preparation for U.S. commercial launch in June 2022 in BBS and Alström syndrome, pending FDA approval -- -- First commercial patients...
May 02, 2022 08:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Presents New Data from Phase 3 Trial Evaluating Setmelanotide in Patients with Bardet-Biedl Syndrome (BBS) at the Pediatric Endocrine Society (PES) 2022 Virtual Annual Meeting

-- New data show setmelanotide treatment led to clinically meaningful improvements in lipid parameters, without affecting blood pressure or heart rate in patients with BBS -- -- Additional posters...
April 26, 2022 08:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022

BOSTON, April 26, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare...
April 08, 2022 08:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

BOSTON, April 08, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare...
April 06, 2022 08:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Optimizes Design of EMANATE and DAYBREAK Clinical Trials to Advance Setmelanotide for Rare Genetic Diseases of Obesity

– Phase 3 EMANATE trial to focus on rare patient populations with highest likelihood for success – – First patient enrolled in EMANATE – – Ongoing Phase 2 DAYBREAK trial to focus initially on 10...
March 01, 2022 16:01 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals to Present at Cowen & Co. 42nd Annual Health Care Conference

BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare...
March 01, 2022 07:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

-- Preparations continue for U.S. commercial launch in June 2022 in BBS and Alström syndrome, pending FDA approval -- -- First commercial sales of IMCIVREE in Germany and France expected in 2Q2022 – ...
February 24, 2022 08:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Bardet-Biedl Syndrome and Alström Syndrome

-- FDA sets updated PDUFA goal date of June 16, 2022 -- -- Company also announces withdrawal of proposed Alström syndrome indication from Type II variation application under review by the EMA -- ...
February 23, 2022 08:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces Promotions within its Executive Leadership Team

BOSTON, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare...
February 22, 2022 08:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on Tuesday, March 1, 2022

BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare...